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ABSTRACT 
	Retinoblastoma is the most common malignant tumour of the eye in childhood, with nearly 
all bilateral tumours and around 17-18% of unilateral tumours due to an oncogenic mutation 
in the RB1 gene in the germline. Genetic testing in all cases enables accurate risk assessment 
and optimal clinical management for the affected individual, siblings, and future offspring.   
We carried out the first UK-wide audit of understanding of genetic testing in individuals with 
retinoblastoma. A total of 292 individuals aged 16-45 years were included. 
Patients with bilateral disease were significantly more likely to understand the implications of 
retinoblastoma for siblings and children. There was a significant association between not 
knowing the results of genetic testing or not understanding the implications and not having 
children, particularly in women. Surprisingly, this was also true for individuals treated for 
unilateral disease with a low risk of retinoblastoma for their offspring. 
We are concerned that individuals may be making life choices based on insufficient 
information regarding risks of retinoblastoma and reproductive options. We suggest that 
improvement in transition care is needed to enable individuals to make informed reproductive 
decisions and to ensure optimal care for children born at risk of retinoblastoma.  
 
KEY WORDS: genetic screening/counselling, paediatric oncology; RB1, retinoblastoma; 
transition care 
 
 
INTRODUCTION 
 
Retinoblastoma is the most common malignant tumour of the eye in childhood, affecting 
approximately 1:20,000 live births 1. It occurs in differentiating cone precursor cells of the 
developing retina that have predisposing mutations in both copies of the tumour suppressor 
gene RB1 2–4. 
Retinoblastoma is bilateral in about 40% of cases with a median age of diagnosis of 12 
months5. The other 60% of affected individuals have unilateral retinoblastoma with a median 
age of diagnosis of 24 months. Nearly all cases of bilateral retinoblastoma, and 17-18% of 
cases of unilateral retinoblastoma 6,7,  are due to an inherited or de novo heterozygous 
germline mutation in RB1 and are therefore subsequently hereditary  segregating in an 
autosomal dominant pattern. The remainder of the bilateral cases and some unilateral cases 
are caused by mosaicism for a mutation, which may be present in the germline. Around 83% 
of unilateral retinoblastoma is non-hereditary, occurring due to somatic mutations in both 
copies of RB1 in the same retinal cell. The heritability of retinoblastoma determines the  risks 
of retinoblastoma for siblings and children of the affected individual, which vary from <1% 
to 50% based on empiric data 7,8. 
Current molecular genetic screening techniques detect up to 95% of germline RB1 mutations 
in leucocytes of individuals with hereditary retinoblastoma 7,9 . Identifying whether or not an 
individual has hereditary retinoblastoma is essential for appropriate clinical management, 
determining the need for frequent follow up examination under anaesthesia (EUA) for early 
detection of newly arising tumours. 
Molecular genetic testing is also essential for optimal management of other family members. 
Detection of a germline RB1 mutation antenatally or postnatally identifies babies at a high 
risk of developing retinoblastoma who will benefit from intensive ophthalmic surveillance 
from birth (Table S1 for Birmingham Children’s Hospital High Risk Screening Protocol). 
Frequent examinations including EUAs enable timely detection of tumours, reducing the 
likelihood that enucleation, radiotherapy, and/or chemotherapy will be required, and helping 
preserve vision and reduce morbidity. Babies who are found not to have inherited the familial 
RB1 mutation do not require ophthalmic surveillance, avoiding unnecessary and burdensome 
EUA and the attendant risks of anaesthesia. In a small number of cases with unilateral 
retinoblastoma where it cannot be proven that the disease is not germline a modified 
screening protocol is followed for the siblings and offspring of the affected family member 
(Table S1 for Birmingham Children’s Hospital Low Risk Screening Protocol).  Identification 
of a germline RB1 mutation also enables new reproductive options such as pre-implantation 
genetic diagnosis (PGD) to be offered.  
Genetic testing is therefore essential for individuals with retinoblastoma to have accurate and 
up to date information for their own clinical management and for that of their children and 
other family members. As part of the standard management of retinoblastoma, it should be 
performed in all individuals irrespective of whether the retinoblastoma is bilateral or 
unilateral, and in this latter group should always include molecular studies on the 
retinoblastoma tumour, where this is available. In this paper we describe the first UK national 
audit assessing individuals’ understanding of the genetic implications of their retinoblastoma 
diagnosis. 
Currently all patients with retinoblastoma in the UK are treated at one of the two nationally 
funded retinoblastoma services. In 1990 a designated national retinoblastoma service was 
commissioned at St Bartholomew’s Hospital in London. Prior to this date, some cases, 
especially isolated unilateral cases would have been managed in local services. Care of 
patients in the West Midlands continued to be provided at the Birmingham Children’s 
Hospital and this became the second national service in 2002. From this date all new cases of 
retinoblastoma were managed by the multi-disciplinary teams (paediatric ophthalmology, 
paediatric oncology, clinical and laboratory genetics, clinical psychology and appropriate 
related specialities) at one or other of these two services. 
 
  
 
 
MATERIALS AND METHODS 
Data collection 
Patients seen in Birmingham were identified from the West Midlands Regional Children’s 
Tumour Registry (WMRCTR) and patients seen in London were identified from local clinical 
records and all cases cross-checked on the National Registry of Childhood Tumours (NRCT).  
The details of all surviving patients diagnosed with retinoblastoma between 1957 and 2008 
were reviewed. Those individuals aged 16 to 45 at the initiation of the project in 2009 were 
contacted over a three year period 2009 to 2012. The general practitioners (GPs) of all 
identified individuals were approached to confirm that it was appropriate to contact the 
patient regarding the audit. Following this initial contact, questionnaire forms were sent out 
to each individual (see Fig. 1). Two versions of the form were sent out (see supplemental 
information Fig. S1), one addressed to the individual (Form A) and the other addressed to the 
parents of the individual with retinoblastoma (Form B). Each family decided which 
questionnaire was the most appropriate to complete. Where a family returned more than one 
questionnaire, as occurred in a very small number of cases, this was readily detectable to the 
authors by matching the names. Where this occurred the information reported by the patient 
rather than the relative was used, as this was the key information the audit was aiming to 
assess. The questions aimed to gather information on individuals’ understanding of the risk of 
retinoblastoma for family members, namely siblings (both forms) and children (Form A 
only). All respondees were asked if they wanted a follow up appointment to go over this 
information and if requested an appointment with their local clinical genetics service was 
arranged.  Following discussion with a local ethics committee member this was deemed to be 
an audit assessing the past implementation of standard clinical practice, not research, and 
therefore formal review by an ethics committee was not required.  
Audit Interpretation 
Each questionnaire was given an ‘Audit Interpretation’ (AI) assessment of the individual’s 
understanding of the genetic implications of their retinoblastoma based on the answers they 
gave to the questions regarding the risk of retinoblastoma for siblings and children. The data 
recorded was the individuals ‘own understanding’ of the retinoblastoma risk and may be 
different to that which was imparted to them, which in many circumstances may be via a 
third party such as their parents, or several different doctors over a period of time. The AI 
was deemed to be ‘Correct’, ‘Incorrect’, ‘No information’ if risks were not given, ‘Out of 
date’ if the risk given was based on out of date information, or ‘Unable to assess’ if the true 
risk was impossible to ascertain based on the clinical information available from the 
questionnaire. All questionnaires were assessed by an experienced genetic counsellor (LB, 
LB, or SC) and verified by a second author single author (TC). There were a very small 
number of cases where a difference of opinion arose. These cases were discussed within the 
genetic counselling and consultant team and a consensus arrived at in all cases. 
 
Exclusion criteria 
Individuals under 16 years of age and older than 45 were excluded for the purposes of this 
audit analysis, which was to assess individuals’ reproductive knowledge at the current time. 
Individuals younger than 16 would most likely have future genetic counselling planned at 
transition or in adulthood and those older than 45 were considered unlikely to be planning 
further children. 
Individuals who did not specify whether their retinoblastoma was unilateral or bilateral were 
also excluded from data analysis.  
 
Laterality 
Cases were grouped into bilateral, hereditary unilateral and non-hereditary unilateral. The 
unilateral cases are divided into hereditary and non-hereditary based on reported family 
history and therefore the true percentage of hereditary cases in the unilateral group will be 
higher due to undetected de novo germline mutations. Throughout the paper, the term ‘non-
hereditary unilateral’ refers to the presumed non-hereditary cases. 
The small number of hereditary unilateral cases are considered as a separate group as 
although the risk of children inheriting the RB1 mutation is 50% as in the bilateral cases, the 
penetrance is much lower. Furthermore, their perception of the significance of unilateral 
disease is likely to be different from those individuals with bilateral disease, having 
significantly less impact for visual impairment and a lower risk for second non-
retinoblastoma primary tumours. 
 
Statistics 
GraphPad software was used to perform Chi-square testing and Fisher’s exact test in 
statistical analysis of the data. 
    
 
 
RESULTS 
 
Demographics and laterality 
575 letters were sent to GPs and 569 replies were received. In six cases it was deemed not 
appropriate to contact the patient and a total of 563 patient letters were sent out. There were 
471 respondents (return rate 84%). 108 were under 16 years of age and 29 were older than 45 
and were therefore excluded. Another 42 individuals did not specify whether their 
retinoblastoma was unilateral or bilateral and were also excluded from data analysis.  
A total of 292 individuals aged 16-45 were therefore included (Fig. 1). Out of these, 230 of 
the questionnaires were completed by individuals themselves and 60 were completed on 
behalf on the individual with retinoblastoma by a parent or guardian. In two cases it was 
unclear whether the individual or a third party had completed the form. These cases were 
excluded from analyses requiring AI but were otherwise included in the results.  At the time 
of participation in the audit, 46% (135/292) were aged 16-25 years old, 27% (79/292) were 
aged 26-35 years old and 27% (78/292) were aged 36-45 years old. The median age was 26 
years and the mean 28.2 years. Form A respondents were older (median 29 years mean 29.7 
years) than Form B respondents (median 19 years mean 22.7 years). 53% (156/292) were 
female and 47% (136/292) male. The laterality of retinoblastoma was 34% (100/292) with 
bilateral disease and 66% (192/292) with unilateral disease. In the unilateral group, 5% 
(9/192) reported a family history of retinoblastoma. In the bilateral group, 25% reported a 
family history of retinoblastoma (Table 1). 
 
Genetic testing rates 
Individuals with bilateral disease were significantly more likely to report having undergone 
genetic testing than those with non-hereditary unilateral disease: 68% (68/100) vs. 36% 
(65/183) (p<0.001, Chi-square test). However, when testing had been performed, individuals 
from both groups were equally likely to recall having received the results of testing, with 
82% (56/68) of the bilateral group and 85% (55/65) of the non-hereditary unilateral group 
knowing the results of genetic tests. 
 
Understanding of genetic test results 
In the bilateral group 77% (53 of the 69 individuals who completed Form A) reported that 
they knew the risk of retinoblastoma for their children and 41% (41/100) for their siblings. 
These figures were significantly lower in the non-hereditary unilateral group, with only 31% 
(47 of the 153 individuals who completed Form A) aware of the risks for children and 17% 
(31/183) for siblings (p<0.001, Chi-square test). 
Only 72% (63/88, excluding out of date/unable to assess/blank responses) of individuals with 
bilateral disease were given an AI score of ‘Correct’ for understanding the genetic 
implications of retinoblastoma, and only 30% (46/154, excluding out of date/unable to 
assess/blank responses) of individuals with non-hereditary unilateral disease. Seven 
individuals in the non-hereditary unilateral group overestimated the risk of retinoblastoma for 
their children as 50%. 
Individuals who had undergone genetic testing and received the results of their tests were 
significantly more likely to correctly assess the chance of retinoblastoma for siblings and/or 
children. 88% of those with bilateral disease (46/52, excluding unable to assess/out of 
date/blank) who knew the results of their genetic tests understood the genetic implications for 
siblings and/or children, compared to only 47% (17/36, excluding unable to assess/out of 
date/blank) of those who did not undergo genetic testing, or had genetic testing and did not 
know the result of testing (p<0.001 Chi-square test). In the non-hereditary unilateral group, 
63% (29/46, excluding unable to assess/out of date/blank) of those who had undergone 
testing and received results understood the genetic implications for siblings and children, 
compared to only 16% (17/108, excluding unable to assess/out of date/blank) of those who 
did not undergo testing or had testing and did not know the result (p<0.001 Chi-square test). 
(Table 2) 
 
 
Requests for appointments to discuss risks for other family members 
Overall 30% (88/292) of individuals requested an appointment to discuss the risk of 
retinoblastoma for other family members: 27% (27/100) of the bilateral group and 32% 
(58/183) of the non-hereditary unilateral group. In the bilateral group, a significantly greater 
proportion (39%, 17/44) of those who did not know the results of genetic testing requested an 
appointment compared to only 18% (10/56) of those who knew the results of genetic testing 
(p=0.0360, Chi-square test). Similarly in the non-hereditary unilateral group, 40% (51/128) of 
those who did not know the results of genetic testing requested an appointment compared to 
only 13% (7/55) of those who knew the results of genetic testing (p=0.0006) (Table 2).  
 
 
Follow up 
In the bilateral group, 48% (48/100) and in the non-hereditary unilateral group 14% (25/183) 
reported attending a long-term follow up clinic with ophthalmology or oncology. Of those not 
under follow up, 48% (24/50, excluding two not answered) in the bilateral group and 45% 
(71/158) in the non-hereditary unilateral group requested follow up in a retinoblastoma clinic. 
In the bilateral group, 60% of individuals aged 16-25 were under long term follow up 
compared to 44% in the 26-35 years age group and 34% of those age 36-45 years. 
 
Reproduction 
67 of the 230 individuals who completed Form A reported having had children (29%), 3% 
(3/88) of the 16-25 age group, 35% of the 26-35 age group (25/72), and 56% (39/70) of the 
36-45 age group. Overall there was no significant difference in fertility rate between the 
bilateral and non-hereditary unilateral groups (bilateral 19/69, 28%; unilateral 45/153, 29%; 
p=0.775, Chi-square test). A greater proportion of the 36-45 age group with non-hereditary 
unilateral disease had children compared to the same age individuals with bilateral disease 
(26/39 67% vs 11/26 42%) but this was not a statistically significant difference (p=0.3, Chi-
square test). 
Individuals who knew the results of genetic testing were significantly more likely to have 
children compared to those who did not know results of genetic testing in the bilateral group 
(16/42 vs 3/27 p=0.0255, Fisher’s exact test) and the non-hereditary unilateral group (23/45 
vs 22/108 p=0.0004, Fisher’s exact test) (Table 2). Individuals who understood the risks of 
retinoblastoma for their children and siblings were significantly more likely to have children 
than those who did not in both the bilateral group (17/48 vs 0/15 p=0.0063, Fisher’s exact 
test) and in the non-hereditary unilateral group (23/40 vs 18/91 p=0.0001, Fisher’s exact test)  
There was no significant difference in fertility between men and women (41/136 women, 
26/94 men p=0.7944 Chi-square test). 
Women who knew the results of genetic testing were significantly more likely to have 
children than those who did not (31/64 vs 10/72 p<0.0001 Chi square test) (Fig. 5). This was 
true in both the bilateral and non-hereditary unilateral groups (bilateral 11/28 vs 0/17 
p=0.0031 Fisher’s exact test; non-hereditary unilateral 19/34 vs 9/52 p=0.0003 Fisher’s exact 
test).Of note, none of the women in the bilateral group who were unaware of their genetic test 
results had children. 
Understanding the genetic implications of retinoblastoma was also significantly associated 
with having children in both groups (bilateral 11/32 vs 0/10 p=0.0411 Fisher’s exact test; 
non-hereditary unilateral 14/24 vs 7/42 p=0.0008 Fisher’s exact test, excluding out of 
date/unable to assess/blank). Women in the bilateral group who did not understand the 
genetic implications of retinoblastoma did not have children. 
There was a trend towards men being more likely to have children if the results of genetic 
testing were known, but this was not statistically significant (10/27 vs 16/67  p=0.300 Chi 
square test) and this was true for both bilateral and non-hereditary unilateral groups (bilateral 
5/14 vs 3/10 p=1 Fisher’s exact test, non-hereditary unilateral 4/11 vs 13/56 p=0.45 Fishers’ 
exact test) (Fig. 5). Men with non-hereditary unilateral disease who understood the genetic 
implications of retinoblastoma were more likely to have children than those who did not 
understand the genetic implications of retinoblastoma (8/15 vs 8/44 Fisher’s exact test 
p=0.016, excluding out of date/unable to assess/blank). Men with bilateral disease who did 
not understand the genetic implications did not have children (0/5 vs 6/16 excluding out of 
date/unable to assess/blank) however the numbers here are very small.  
 
 
DISCUSSION 
Rates of genetic testing 
Overall, the audit found that reported rates of genetic testing were surprisingly low in both 
unilateral and bilateral groups. Part of the explanation for this is that genetic testing only 
became routinely available in the mid to late 1990s for bilateral retinoblastoma and even later 
for unilateral retinoblastoma. The participants in the audit were all born before 1995 and 
therefore would not have been offered testing at the time of diagnosis, and would have had to 
be offered or seek testing at a later date. It is now routine practice to offer genetic testing in 
all cases of retinoblastoma. 
An additional potential reason for low reported rates of genetic testing is that because of the 
natural history of retinoblastoma, patients will be diagnosed and undergo testing in 
childhood, and therefore as adults may be unaware of previous genetic testing. It is possible 
that in some cases, parents might have withheld information from a child in an effort to 
protect the child from worrisome news. Knowledge of having had a genetic test depends on 
this information being passed on by a parent, or through a follow up appointment in 
adolescence or adulthood with the healthcare system.  
 
Understanding of genetic test results 
Individuals with bilateral retinoblastoma were more likely to be able to give accurate risks for 
siblings and children. This may be due to the fact that genetic test results in unilateral 
retinoblastoma are more likely to be incomplete or uninformative and more complicated than 
in bilateral disease and therefore assessing risk is more complex. In addition, as patients with 
unilateral retinoblastoma are usually discharged from national follow up before the early 
teenage years, individuals may be reliant solely on their parents for the communication of this 
information. However even in bilateral retinoblastoma, where assessment of recurrence risk 
is straightforward and individuals might be expected to be in long-term follow up, over a 
quarter of individuals were not able to correctly assess the recurrence risks for their siblings 
and children. Less than half of individuals with bilateral retinoblastoma in the audit reported 
attending a long-term follow up clinic, suggesting that many individuals rely on their parents 
as a source of information. Previous research has identified a number of reasons why 
communication of genetic information in retinoblastoma from parent to child may fail, 
including the difficulty of recalling information received at a time that is very stressful, and in 
some cases a reluctance to discuss issues around genetic risk10. 
 
Requests for appointments to discuss risks for other family members 
The results indicated that a number of individuals who did not know their genetic test results 
or risks to family members wished to have this information and requested an appointment 
with clinical genetics. The study has enabled these individuals to access this information 
through appointments with their local clinical genetics service.  The identification that 40% 
of responders in the single largest group (unilateral non hereditary without genetic 
information) requested an appointment identifies a significant unmet need. This is especially 
concerning in the group that are at mostly at low risk of having an affected child.  
 
 
Follow up 
Long term follow up for retinoblastoma in the UK is typically organised back with the 
referring centre, especially for unilateral disease. It should however include oncology input in 
a ‘late effects’ service for those who had bilateral disease or any case that required either 
chemotherapy or radiotherapy. 48% of individuals with bilateral retinoblastoma and 14% of 
those with unilateral retinoblastoma reported being under long-term follow-up. Of those 
individuals not currently under follow up with oncology or ophthalmology, almost half 
requested that this be arranged. This was true for both unilateral and bilateral groups, 
indicating a clear desire by adults with retinoblastoma for ongoing medical follow up. 
 
Reproduction 
Overall a surprisingly low proportion of the cohort reported having children, for example 
38% (14/37) of women in the 36-45 years age group did not have children compared to 19% 
of 45 year old women in the general population in the UK11. We identified a clear relationship 
between genetic testing and understanding the genetic implications of retinoblastoma and 
having children in both unilateral and bilateral groups, which was especially striking in 
female participants. From the audit data we cannot identify the cause and effect. The 
association may be due to individuals wanting children actively seeking out genetic testing; 
alternatively, it may be that individuals who are unaware of therisks and reproductive choices 
are deciding not to have children. Our finding that over 80% (43/52) of women with non-
hereditary unilateral retinoblastoma who were unaware of genetic test results had no children 
might suggest that it is the lack of genetic information that is influencing reproductive 
decisions. 
Previous work exploring reproductive decision making in retinoblastoma has identified 
patient perception of risk as an important factor. Dommering et al. found that retinoblastoma 
had a significant impact on reproductive behaviour in a cohort of patients who had undergone 
genetic testing, with perceived risk as opposed to actual risk being the most important 
factor12,13. A study of other inherited retinal disorders identified that affected individuals had 
a deep anxiety about passing on visual impairment to their children, and some had chosen not 
to have children because the risk was ‘too high’14.  
We must also consider that a lack of clinical information patients have regarding 
developments in treatment of retinoblastoma and an “unawareness” of better outcomes 
compared to the past might be influencing individuals’ decisions not to have children. Many 
children under surveillance because of an identified risk of retinoblastoma will now be 
treated by local therapy only (e.g. laser/cryotherapy) and avoid the morbidity associated with 
enucleation, chemotherapy and/or external beam radiotherapy. Individuals who have 
experienced the morbidity associated with older treatments may choose not to have children 
to avoid side effects they feel are unacceptable and not be aware of these new therapies. 
Follow up in a late effects clinic would give patients the opportunity to discuss future 
management and outcomes.  
A lack of information regarding new reproductive technologies such as PGD may also be 
playing an important role. We found 100% of women with bilateral retinoblastoma who did 
not know their genetic test results had no children, a highly surprising figure. This may 
reflect a lack of awareness of the options now available that enable individuals to have 
children without retinoblastoma and anecdotal evidence of this was seen in the audit. 
There are potentially other confounding factors, such as social factors, body image, and self-
esteem issues that may be related to facial asymmetry or visual impairment, many of which 
will be avoided with newer treatment, but which may still be  influencing reproductive rates 
in individuals with retinoblastoma. Further investigation, ideally through a qualitative 
research study, is warranted to explore the reasons for the low reproductive rates in 
individuals with retinoblastoma identified by this study.   
 
The results of this large scale national audit suggest that individuals may be making life 
choices based on incomplete or inaccurate information. It is vital for health care professionals 
to ensure young adults who were diagnosed with retinoblastoma in childhood have up to date 
genetic test results and fully understand the implications of these results. This is necessary to 
inform their own medical care, to enable them to make informed reproductive decisions, and 
to ensure that optimal care is provided to children who are born at risk of retinoblastoma. In 
this era of mainstreaming genetics we must ensure that embedding clinical genetics in 
transition care is seen as a priority. 
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LEGENDS  
 
Figure 1. Flowchart of participant inclusion and exclusion 
 
 
 Figure 2 The percentage of respondents who had children. Knowing the results of genetic 
testing was significantly associated with having children in female respondents but not male 
respondents. 
 
Figure S1. Questionnaires sent to participants, Forms A and B 
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Questionnaires 
 
FORM A 
Personal details 
Name 
Sex: M / F 
Date of birth 
a. Age when retinoblastoma was diagnosed 
b. Mother’s date of birth 
c. Father’s date of birth 
Q1. Which eyes are affected? Right eye only / Left eye only / Both eyes / Don’t know 
Q2. Have both your parents had their eyes checked to exclude a healed/regressed 
retinoblastoma (scar on the back of the eye)? Yes / No / Don’t know 
Q3. Has anybody else in the family had a retinoblastoma? Yes / No / Don’t know 
Q4. Have you had blood taken for a gene test? Yes (go to Q5) /  No (go to Q7) / Don’t know 
(go to Q7) 
Q5. When was the gene test carried out? 
Q6. Have you had the result of the gene test?  Yes / No / Don’t know 
Q7. Do you have any children? Yes (go to Q8) / No (go to Q9) 
Q8. Please enter your children’s details 
Name Sex Current 
age 
Have they had a 
gene test? 
Have they had 
eye exams? 
Have they had a 
retinoblastoma? 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
Q9. Do you know how likely retinoblastoma is for your current / any future children? Yes (go 
to Q10) / No (go to Q11) / Don’t know (go to Q11) 
Q.10 Please tick the box that you think best describes the chance that your current / any 
future children will develop retinoblastoma: 5% or less (1 in 20 chance) / 50% (1 in 2 chance) 
/ close to 100% (almost certain to) / Don’t know 
Q11. Do you have any brother or sisters? Yes (go to Q12) / No (go to Q15) / Don’t know (go 
to Q15) 
Q12. Please enter your brothers’ / sisters’ details below 
Name Sex Current 
age 
Have they had a 
gene test? 
Have they had 
eye exams? 
Have they had a 
retinoblastoma? 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 
Q13. Do you know how likely retinoblastoma was for your brothers / sisters? Yes (go to 
Q14) / No (go to Q15) / Don’t know (go to Q15) 
Q14. Please tick the box that you think best describes the chance that any of your 
brothers/sisters named above would develop a retinoblastoma: 5% or less (1 in 20 chance) / 
50% (1 in 2 chance) / close to 100% (almost certain to) / Don’t know 
Q15. Would you like an appointment to go over any of this information? Yes / No 
Q16. Are you aware of any pregnancies in the family that were the result of assisted 
reproductive techniques, such as egg or sperm donation or IVF (test tube pregnancy)? Yes / 
No / Don’t know 
Q17. Are you attending a long-term follow up clinic (either Ophthalmology or Oncology)? 
Yes / No 
Q18. The current national recommendations are for some patients, diagnosed with 
retinoblastoma, to receive regular outpatient appointments, even into adulthood. If you are 
not on any form of follow up – would you like an appointment in a retinoblastoma follow-up 
clinic to be arranged? 
Please use this space to add further information: 
  
 FORM B 
Details of person with retinoblastoma 
Name 
Sex: M / F 
Date of birth 
Age when retinoblastoma was diagnosed 
Mother’s date of birth 
Father’s date of birth 
Details of person completing this form 
  Name 
  Relationship to person with retinoblastoma 
Q1. Which eyes are affected in the person with retinoblastoma? Right eye only / Left eye 
only / Both eyes / Don’t know 
Q2. Have both parents had their eyes checked to exclude a healed/regressed retinoblastoma 
(scar on the back of the eye)? Yes / No / Don’t know 
Q3. Has anybody else in the family had a retinoblastoma? Yes / No / Don’t know 
Q4. Has blood been taken from the person with retinoblastoma for a gene test? Yes (go to 
Q5) /  No (go to Q7) / Don’t know (go to Q7) 
Q5. When was the gene test carried out? 
Q6. Have you had the result of the gene test?  Yes / No / Don’t know 
Q7. Does the person with retinoblastoma have any brothers or sisters? Yes (go to Q8) / No 
(go to Q11) 
Q8. Please enter the brothers’/sisters’ details below 
Name Sex Current 
age 
Have they had a 
gene test? 
Have they had 
eye exams? 
Have they had a 
retinoblastoma? 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 M/F  Yes/No/Don’t 
know 
Yes/No/Don’t 
know 
Yes/No/Don’t know 
 
Q9. Do you know how likely it is that any current/future brothers or sisters would develop a  
retinoblastoma? Yes (go to Q10) / No (go to Q11) / Don’t know (go to Q11) 
Q10. Please tick the box that you think best describes the chance that any current / future 
brothers or sisters would develop a retinoblastoma: 5% or less (1 in 20 chance) / 50% (1 in 2 
chance) / close to 100% (almost certain to) / Don’t know 
Q11. Would you like an appointment to go over any of this information? Yes / No 
Q12. Are you aware of any pregnancies in the family that were the result of assisted 
reproductive techniques, such as egg or sperm donation or IVF (test tube pregnancy)? Yes / 
No / Don’t know 
Q13. Are you attending a long-term follow up clinic (either Ophthalmology or Oncology)? 
Yes / No 
Q14. The current national recommendations are for some patients, diagnosed with 
retinoblastoma, to receive regular outpatient appointments, even into adulthood. If you are 
not on any form of follow up – would you like an appointment in a retinoblastoma follow-up 
clinic to be arranged? 
Please use this space to add further information: 
	
	 	
Table 1: Summary of results 
 
 
Bilateral Non-hereditary 
unilateral 
Hereditary 
unilateral 
Total 
Number of individuals 100 183 9 292 
Form completed*        
Form A 
Form B 
 
69 
31 
 
153 
28 
 
8 
1 
 
230 
60 
Sex  
Male 
Female 
 
44 
56 
 
88 
95 
 
4 
5 
 
136 
156 
Age 
16-25 
26-35 
36-45 
 
43 
25 
32 
 
90 
52 
41 
 
2 
2 
5 
 
135 
79 
78 
Family history Rb 
Yes 
No 
Don’t know 
 
25 
72 
3 
 
0 
171 
12 
 
9 
0 
0 
 
34 
243 
15 
Genetic testing performed 
Yes 
No 
Don’t know 
Not answered 
 
68 
20 
12 
0 
 
65 
83 
33 
2 
 
6 
1 
2 
0 
 
139 
104 
47 
2 
Result of genetic test known 
Yes 
No 
Don’t know 
Not answered 
 
56 
5 
8 
31 
 
55 
12 
8 
108 
 
5 
2 
0 
2 
 
116 
19 
16 
141 
Know how likely Rb is for 
children^ 
Yes 
No 
Don’t know 
Not answered 
 
 
53 
10 
6 
0 
 
 
47 
65 
40 
1 
 
 
5 
0 
3 
0 
 
 
105 
75 
49 
1 
Know how likely Rb is for 
siblings 
Yes 
No 
Don’t know 
Not answered 
 
 
41 
27 
16 
16 
 
 
31 
79 
58 
15 
 
 
4 
1 
3 
1 
 
 
76 
107 
77 
32 
Would like an appointment  
Yes 
No 
Not answered 
 
27 
62 
11 
 
58 
113 
12 
 
3 
5 
1 
 
88 
180 
24 
Attending long-term follow up 
Yes 
No 
Not answered 
 
48 
50 
2 
 
25 
157 
1 
 
2 
7 
0 
 
75 
214 
3 
Would like to be under follow up 
Yes 
No 
Not answered 
 
30 
34 
36 
 
81 
76 
26 
 
4 
4 
1 
 
115 
114 
63 
Have children^ 
Yes 
No 
Not answered 
 
19 
49 
1 
 
45 
106 
2 
 
3 
5 
0 
 
67 
160 
3 
*in two cases in was unclear whether the individual or a third party had completed the form 
^ Form A respondees only 
Table	2:	Respondents	who	knew	their	genetic	test	results	were	significantly	more	likely	to	correctly	
assess	the	risk	of	retinoblastoma	for	siblings	and/or	children,	significantly	less	likely	to	request	a	
review	appointment	with	clinical	genetics,	and	significantly	more	likely	to	have	children	than	those	
who	did	not	know	their	genetic	test	results	
	
	 	 Bilateral	disease	 Non-hereditary	
unilateral	disease	
Genetic	
test	results	
known	
Correct	understanding	of	implications	for	
siblings	and/or	children	
46/52	
(88%)	
29/46	
(63%)	
Requested	review	appointment	with	
clinical	genetics	
10/56	
(18%)	
7/55	
(13%)	
Had	children	
	
16/42	
(38%)	
23/45	
(51%)	
Genetic	
test	results	
not	known	
Correct	understanding	of	implications	for	
family	members	
17/36	
(47%)	
17/108	
(16%)	
Requested	review	appointment	with	
clinical	genetics	
17/44	
(39%)	
51/128	
(40%)	
Had	children	
	
3/27	
(11%)	
22/108	
(20%)	
	
	
  
Table S1: Birmingham Children’s Hospital NHS Foundation Trust protocols for screening 
siblings and offspring of patients with retinoblastoma 
 
AGE HIGH RISK SCREENING PROTOCOL 
  Dilated fundus examination 
Within a week of birth Awake examination, no anaesthetic 
1 week – 6 months Monthly awake examination, no anaesthetic 
6 months – 2 years Examination every 2 months  
2 years – 3 years Examination every 3 months 
3 years – 4 years Examination every 4 months 
4 years – 7 years Examination every 6 months 
 
 
AGE LOW RISK SCREENING PROTOCOL 
  Dilated fundus examination 
Within a week of birth Awake examination, no anaesthetic 
1 week – 6 months Monthly awake examination, no anaesthetic 
6 months – 3 years Examination every 3 months with EUA at least every 6 months 
3 years – 5 years Examination every 6 months -Most examinations will be undertaken 
without anaesthetic, but clinical priority remains exclusion of 
retinoblastoma, so the ophthalmologist may still feel EUA’s 
indicated at some points on the protocol for some individuals 
 
 
	 	
	
